{
  "questions": [
    {
      "type": "factoid",
      "id": "64403ab057b1c7a31500004d",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "two",
          0.9986900896262174
        ],
        [
          "two suprachoroidal injections of CLS-TA at 0 and 12 weeks",
          0.0008305057027046923
        ],
        [
          "two suprachoroidal injections",
          0.0001924950935248105
        ],
        [
          "two suprachoroidal",
          0.00015356673159612325
        ],
        [
          "two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
          7.486464444041228e-05
        ],
        [
          "two suprachoroidal injection",
          1.3812756828540674e-05
        ],
        [
          "two suprachoroidal injections of CLS-TA",
          1.1370643542992816e-05
        ],
        [
          "phase III trial with two",
          2.8388423259752267e-06
        ],
        [
          "suprachoroidal injections of CLS-TA at 0 and 12 weeks",
          1.462339945935604e-07
        ],
        [
          "suprachoroidal injections",
          3.389420009293212e-08
        ],
        [
          "NCT02595398",
          3.291926797577701e-08
        ],
        [
          "suprachoroidal",
          2.703976206887441e-08
        ],
        [
          "suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
          9.722860574458619e-09
        ],
        [
          "0 and 12 weeks",
          9.657154215467883e-09
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6411b678201352f04a000036",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "acquired",
          1.9850729511400749
        ],
        [
          "autosomal dominant",
          0.9433779186992856
        ],
        [
          "autosomal dominant mode of inheritance",
          0.037165048513284324
        ],
        [
          "Congenital",
          0.013000127057529254
        ],
        [
          "acquired prosopagnosia",
          0.009974789988252382
        ],
        [
          "In contrast to the acquired",
          0.002730119184560784
        ],
        [
          "inherited in an autosomal dominant",
          0.002560307377132861
        ],
        [
          "prosopagnosia",
          0.0016004437451165722
        ],
        [
          "There is evidence that it can be inherited in an autosomal dominant",
          0.0013966232734820062
        ],
        [
          "an autosomal dominant",
          0.0012111782328599564
        ],
        [
          "in an autosomal dominant",
          0.0006902469011868004
        ],
        [
          "the acquired",
          0.0002686370120481657
        ],
        [
          "acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal",
          0.00011691043393217827
        ],
        [
          "auto",
          9.184098886504608e-05
        ],
        [
          "Congenital prosopagnosia (cPA)",
          8.199445022265346e-05
        ],
        [
          "inherited in an autosomal dominant mode of inheritance",
          7.959906838364343e-05
        ],
        [
          "acquired form",
          7.574299450681324e-05
        ],
        [
          "autosomal dominant mode",
          6.844678921694175e-05
        ],
        [
          "Congenital prosopagnosia",
          5.911941574399017e-05
        ],
        [
          "There is evidence that it can be inherited in an autosomal dominant mode of inheritance",
          4.34205331926102e-05
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "643bc8f957b1c7a31500002b",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Promoters",
          0.7862742181116614
        ],
        [
          "Promoters mark the start of every transcript and are an important class of regulatory elements",
          0.21028847727359024
        ],
        [
          "A promoter is a short region of DNA (100-1,000 bp)",
          0.06412931487221799
        ],
        [
          "directly upstream or at the 5' end of the transcription initiation site",
          0.052747485155227626
        ],
        [
          "5' end of the transcription initiation site",
          0.045095486609633334
        ],
        [
          "upstream or at the 5' end of the transcription initiation site",
          0.006227639058027926
        ],
        [
          "100-1,000 bp) where transcription of a gene by RNA polymerase begins",
          0.0031306350382851716
        ],
        [
          "It is typically located directly upstream or at the 5' end of the transcription initiation site",
          0.0027100045448319385
        ],
        [
          "A promoter",
          0.002590162560890331
        ],
        [
          "at the 5' end of the transcription initiation site",
          0.0020050678882808527
        ],
        [
          "short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins",
          0.0019659922152327263
        ],
        [
          "Promote",
          0.0019327369699172804
        ],
        [
          "directly upstream",
          0.0017073658258254009
        ],
        [
          "a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins",
          0.0016368065396747216
        ],
        [
          "1,000 bp) where transcription of a gene by RNA polymerase begins",
          0.0013811718238322655
        ],
        [
          "the 5' end of the transcription initiation site",
          0.0013601126407930828
        ],
        [
          "A promoter is a short region",
          0.0010699063135095625
        ],
        [
          "Pro",
          0.0010642956511154682
        ],
        [
          "A promoter is a short region of DNA",
          0.000606541893155335
        ],
        [
          "Promoters mark the start of every transcript",
          0.0002550951240608755
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64403be357b1c7a31500004e",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "24 weeks",
          0.9976636178662328
        ],
        [
          "24",
          0.0013434660597469476
        ],
        [
          "0 and 12 weeks with follow up lasting 24 weeks",
          0.0006670978328691759
        ],
        [
          "12 weeks with follow up lasting 24 weeks",
          0.00029657013689515885
        ],
        [
          "weeks",
          1.3719758076264751e-05
        ],
        [
          "0 and 12 weeks",
          2.9579052997171806e-06
        ],
        [
          "12 weeks",
          1.314989101204399e-06
        ],
        [
          "two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
          9.15471020629761e-07
        ],
        [
          "0 and 12 weeks with follow up lasting 24",
          8.983244282038609e-07
        ],
        [
          "at 0 and 12 weeks with follow up lasting 24 weeks",
          6.095767118118863e-07
        ],
        [
          "suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
          5.4761071231e-07
        ],
        [
          "CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
          4.4704573640301305e-07
        ],
        [
          "12 weeks with follow up lasting 24",
          3.9936600828522107e-07
        ],
        [
          "weeks with follow up lasting 24 weeks",
          3.700237964025417e-07
        ],
        [
          "follow up lasting 24 weeks",
          1.466811927501732e-07
        ],
        [
          "and 12 weeks with follow up lasting 24 weeks",
          1.1409758866640436e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6440396957b1c7a31500004b",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Suprachoroidal",
          1.7666317062362014
        ],
        [
          "Suprachoroidal delivery",
          0.1196490716073969
        ],
        [
          "Suprachoroidal (SC)",
          0.024369265312659098
        ],
        [
          "Microinjector",
          0.020439061429999423
        ],
        [
          "suprachoroidal space (SCS\u00ae)",
          0.012462735703395523
        ],
        [
          "Suprachoroidal (SC) delivery",
          0.00987540408719638
        ],
        [
          "SCS Microinjector",
          0.00915469860025502
        ],
        [
          "suprachoroidal space",
          0.008512558095094842
        ],
        [
          "Microinjector\u00ae. Suprachoroidal",
          0.007426702405076667
        ],
        [
          "Su",
          0.0037423766182602828
        ],
        [
          "SCS Microinjector\u00ae. Suprachoroidal",
          0.0033264356264654502
        ],
        [
          "suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA",
          0.0020081316661943785
        ],
        [
          "microneedle-based device, the SCS Microinjector",
          0.0010836136905177736
        ],
        [
          "Microinjector\u00ae",
          0.000846858346011505
        ],
        [
          "the SCS Microinjector",
          0.0004109808690100204
        ],
        [
          "microneedle-based device, the SCS Microinjector\u00ae. Suprachoroidal",
          0.00039374001732439524
        ],
        [
          "SCS Microinjector\u00ae",
          0.00037930963422159574
        ],
        [
          "Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions",
          0.000319802209757539
        ],
        [
          "Supra",
          4.48617448556464e-05
        ],
        [
          "Suprachoroidal delivery enables",
          2.1906048101915757e-06
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6431708a57b1c7a315000017",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "cardiomyocytes",
          1.008864849390762
        ],
        [
          "miR-145",
          0.9892009890804146
        ],
        [
          "T1AM",
          0.8341838030722304
        ],
        [
          "T1AM on cardiomyocytes",
          0.05755880075973569
        ],
        [
          "145",
          0.008000987108924846
        ],
        [
          "cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP)",
          0.007496864334761885
        ],
        [
          "Stretching of cultured cardiomyocytes",
          0.003952474498647781
        ],
        [
          "cardiomyocytes, after up-regulating the expression of miR-145",
          0.0017113023431099736
        ],
        [
          "brain natriuretic peptide (BNP)",
          0.0014888936726272536
        ],
        [
          "cardiomyocytes up-regulates the expression of brain natriuretic peptide",
          0.0009711386457327237
        ],
        [
          "A",
          0.0009050076092947285
        ],
        [
          "T1",
          0.0007424796715817272
        ],
        [
          "B-type natriuretic peptide (BNP) induced by PE decreased",
          0.000415452950160494
        ],
        [
          "T",
          0.0004111896483837002
        ],
        [
          "In hypertrophic cardiomyocytes, after up-regulating the expression of miR-145",
          0.0002599790401545124
        ],
        [
          "T1AM on card",
          0.00023376342281301488
        ],
        [
          "hypertrophic cardiomyocytes, after up-regulating the expression of miR-145",
          0.00020779517839891992
        ],
        [
          "brain natriuretic peptide",
          0.00019287026152663836
        ],
        [
          "cardiomy",
          0.00017398849426833386
        ],
        [
          "card",
          0.0001521077405565808
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "640f8641201352f04a00002c",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "eyes",
          0.999393168539312
        ],
        [
          "subscleral",
          0.996242120532214
        ],
        [
          "P",
          0.809197211696602
        ],
        [
          "trabeculotomy",
          0.7834705791163179
        ],
        [
          "3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
          0.2763436446368595
        ],
        [
          "Glaucoma Surgery Devices",
          0.27333846549784296
        ],
        [
          "Microinvasive Glaucoma Surgery Devices",
          0.22072162476716747
        ],
        [
          "Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
          0.13589812109826613
        ],
        [
          "trab",
          0.06154741954034232
        ],
        [
          "This retrospective case series included patients with PCG who underwent trab",
          0.03820147813186549
        ],
        [
          "Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
          0.03792274949527219
        ],
        [
          "of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
          0.02780647624913074
        ],
        [
          "Paired comparisons, randomized design, baseline-controlled study.P",
          0.02745670799893234
        ],
        [
          "outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P",
          0.025289577124377193
        ],
        [
          "DESIGN: Paired comparisons, randomized design, baseline-controlled study.P",
          0.02415455369557313
        ],
        [
          "trabeculotomy using an illuminated microcatheter",
          0.02213561885613231
        ],
        [
          "baseline-controlled study.P",
          0.021457285567135404
        ],
        [
          "glaucoma surgery (MIGS) devices on outflow facility.DESIGN:",
          0.020709014305465415
        ],
        [
          "randomized design, baseline-controlled study.P",
          0.018727250041321978
        ],
        [
          "'s Canal Microinvasive Glaucoma Surgery Devices",
          0.017384891379129973
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644009c557b1c7a315000041",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "autosomal recessive",
          0.9996168202025265
        ],
        [
          "recessive",
          0.00013679616430245425
        ],
        [
          "autosomal recess",
          0.00010338449226646179
        ],
        [
          "auto",
          9.244223414778305e-05
        ],
        [
          "Friedreich's Ataxia (FRDA) is an autosomal recessive",
          4.0448783825286865e-05
        ],
        [
          "autosomal re",
          3.5529765592894065e-06
        ],
        [
          "autosomal recessive neurodegenerative disorder",
          2.20420183175165e-06
        ],
        [
          "an autosomal recessive",
          9.126845854646636e-07
        ],
        [
          "autosomal",
          7.07035086417319e-07
        ],
        [
          "autoso",
          5.003300452395794e-07
        ],
        [
          "(FRDA) is an autosomal recessive",
          3.72881853746474e-07
        ],
        [
          "Ataxia (FRDA) is an autosomal recessive",
          9.404047988403919e-08
        ],
        [
          "autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia",
          9.088818723366464e-08
        ],
        [
          "autosomal recessive neurodegenerative",
          6.434043103218857e-08
        ],
        [
          "autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG)",
          4.862435766738082e-08
        ],
        [
          "Friedreich's Ataxia (FRDA) is an autosomal recess",
          4.183379965260998e-09
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64371a4257b1c7a315000029",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "operons",
          1.7270621222378304
        ],
        [
          "Clustering of functionally related genes in operons",
          0.7114261264568054
        ],
        [
          "polycistronic messages (operons)",
          0.08200760048614336
        ],
        [
          "polycistronic messages",
          0.017300417545852518
        ],
        [
          "Clustering of functionally related genes in operon",
          0.015629086541921525
        ],
        [
          "operon",
          0.013716585738188571
        ],
        [
          "operons is a fundamental element of how genetic information is organized in prokaryotes",
          0.0017065629337912043
        ],
        [
          "Prokaryotes evolved polycistronic messages (operons)",
          0.0013701832430199198
        ],
        [
          "operons allows for coregulated gene expression in prokaryotes",
          0.0011739312797470153
        ],
        [
          "The arrangement of functionally-related genes in operons",
          0.00045665159267875517
        ],
        [
          "Prokaryotes evolved polycistronic messages",
          0.0002890554299607907
        ],
        [
          "Clustering of functionally related genes in operons allows for coregulated gene expression",
          0.0001604518291912327
        ],
        [
          "op",
          7.915087131622688e-05
        ],
        [
          "in operons",
          7.254743858915826e-05
        ],
        [
          "Clustering",
          6.264897195455102e-05
        ],
        [
          "operons allows for coregulated gene expression",
          5.9172878739414827e-05
        ],
        [
          "C",
          5.218090898486391e-05
        ],
        [
          "Cluster",
          3.5604494303538205e-05
        ],
        [
          "Clustering of functionally related genes in op",
          2.2774703472297564e-05
        ],
        [
          "Clustering of functionally related genes in operons allows",
          4.0860947754640215e-06
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6440377c57b1c7a315000049",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "triamcinolone acetonide",
          0.6361403415798683
        ],
        [
          "triamcinolone",
          0.35979825971621565
        ],
        [
          "acetonide",
          0.0030187900123452645
        ],
        [
          "CLS-TA, a triamcinolone acetonide",
          0.0006350571212262369
        ],
        [
          "CLS-TA, a triamcinolone",
          0.00035918559491153137
        ],
        [
          "triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae)",
          5.7131535107424065e-06
        ],
        [
          "a triamcinolone acetonide",
          2.540011290498683e-06
        ],
        [
          "t",
          2.0161467290511066e-06
        ],
        [
          "a triamcinolone",
          1.4366195354177592e-06
        ],
        [
          "2021 FDA approval of CLS-TA, a triamcinolone acetonide",
          1.4122273743120425e-06
        ],
        [
          "tria",
          9.69074303320583e-07
        ],
        [
          "the 2021 FDA approval of CLS-TA, a triamcinolone acetonide",
          8.520293766372316e-07
        ],
        [
          "2021 FDA approval of CLS-TA, a triamcinolone",
          7.987497701201498e-07
        ],
        [
          "triamcinolone ace",
          7.131968062955627e-07
        ],
        [
          "the 2021 FDA approval of CLS-TA, a triamcinolone",
          4.819041757040951e-07
        ],
        [
          "triamcin",
          4.742696359924873e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6441057657b1c7a315000052",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "FLACC",
          2.03339861654629
        ],
        [
          "FLACC and COMFORT",
          0.8547113331284549
        ],
        [
          "Wong-Baker Faces Pain Rating Scale",
          0.7854358254615957
        ],
        [
          "FLACC-r",
          0.7362943066678045
        ],
        [
          "Wong-Baker Faces",
          0.10720876025450889
        ],
        [
          "Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC)",
          0.04991301927601331
        ],
        [
          "COMFORT",
          0.03143073475076113
        ],
        [
          "Face, Legs, Activity, Cry, Consolability-revised scale",
          0.010160991336297961
        ],
        [
          "the Wong-Baker Faces Pain Rating Scale",
          0.0064419053610129985
        ],
        [
          "FLACC and COMFORT scales",
          0.005466363243459506
        ],
        [
          "The FLACC and COMFORT",
          0.004369053211493463
        ],
        [
          "Faces Pain Rating Scale",
          0.0038524746268234567
        ],
        [
          "Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale",
          0.00377657234261451
        ],
        [
          "Wong-Baker Faces Pain",
          0.003483243447294429
        ],
        [
          "Face, Legs, Activity, Cry, and Consolability (FLACC) scale",
          0.0033360762469511287
        ],
        [
          "Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r)",
          0.002023911641189708
        ],
        [
          "Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability",
          0.0019002245139774993
        ],
        [
          "pain was assessed using the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale",
          0.0017953735465601754
        ],
        [
          "Wong-Baker",
          0.0015928086488611326
        ],
        [
          "the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale",
          0.0013162946742779548
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64257c9c690f196b5100004b",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "early detection of drug's hepatotoxicity in clinical drug development",
          0.9288734138526871
        ],
        [
          "phenotype-based drug-induced liver injury causality assessment tool",
          0.8011136954230054
        ],
        [
          "drug-specific liver injury phenotypes",
          0.40648252663750495
        ],
        [
          "DILI causality assessment tool",
          0.2090560627155841
        ],
        [
          "liver injury phenotypes",
          0.18784925620303952
        ],
        [
          "A novel phenotype-based drug-induced liver injury causality assessment tool",
          0.10935868354948253
        ],
        [
          "DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes",
          0.09573744612807791
        ],
        [
          "uses drug-specific liver injury phenotypes",
          0.026379398158374128
        ],
        [
          "liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development",
          0.020337852519300342
        ],
        [
          "drug-induced liver injury causality assessment tool",
          0.011802723293228103
        ],
        [
          "computer-assisted scoring algorithm",
          0.005830323485672138
        ],
        [
          "allows for signal confirmation in early drug development",
          0.00581716840342255
        ],
        [
          "hepatotoxicity in clinical drug development",
          0.004245367326645999
        ],
        [
          "early detection of drug's hepatotoxicity",
          0.00418747291688899
        ],
        [
          "We utilised a novel DILI causality assessment tool",
          0.0028150026906972425
        ],
        [
          "novel phenotype-based drug-induced liver injury causality assessment tool",
          0.002521676867700843
        ],
        [
          "novel DILI causality assessment tool",
          0.0015244827090629346
        ],
        [
          "development",
          0.0014077084330858768
        ],
        [
          "drug's hepatotoxicity in clinical drug development",
          0.0011761021296311366
        ],
        [
          "signal confirmation in early drug development",
          0.0011469279450424333
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6429e85e57b1c7a315000009",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "riboswitches",
          2.0131014650611005
        ],
        [
          "riboswitches are typically located in noncoding regions of mRNA",
          0.6760441631655714
        ],
        [
          "Metabolite-sensing mRNAs, or \"riboswitches",
          0.46552370089627093
        ],
        [
          "Riboswitch",
          0.17463387475796668
        ],
        [
          "riboswitches might be representatives of an ancient form of genetic control",
          0.14260659690683292
        ],
        [
          "Metabolite-sensing mRNAs, or \"riboswitches,\"",
          0.05920304444478739
        ],
        [
          "Metabolite-sensing mRNAs, or \"riboswitch",
          0.03844634671214473
        ],
        [
          "Metabolite-sensing mRNAs",
          0.03020507446487838
        ],
        [
          "metabolism",
          0.023002068181862404
        ],
        [
          "These riboswitches are typically located in noncoding regions of mRNA",
          0.01565528984965803
        ],
        [
          "Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes",
          0.013394828234286222
        ],
        [
          "direct expression of the genes involved in their metabolism",
          0.012934080539623258
        ],
        [
          "Riboswitches contain sensing \"aptamer\" modules",
          0.012616518265163624
        ],
        [
          "riboswitches,\"",
          0.007124807968163081
        ],
        [
          "These riboswitches",
          0.0063486409574752
        ],
        [
          "mRNAs is widespread in prokaryotes. These riboswitches",
          0.0037616614185052885
        ],
        [
          "mRNAs is widespread in prokaryotes",
          0.0026038794673081188
        ],
        [
          "R",
          0.001972433527585659
        ],
        [
          "Genetic control by metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches",
          0.0018944260768136557
        ],
        [
          "mRNAs",
          0.001592691396330849
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6440393157b1c7a31500004a",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "2021",
          0.9999122771933793
        ],
        [
          "202",
          8.490710894390169e-05
        ],
        [
          "the 2021",
          1.2145940493573004e-06
        ],
        [
          "2021 FDA approval of CLS-TA",
          1.0364205487094766e-06
        ],
        [
          "after the 2021",
          3.7292946630208743e-07
        ],
        [
          "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021",
          6.418723760016328e-08
        ],
        [
          "suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021",
          3.3059259930113815e-08
        ],
        [
          "2021 FDA approval of CLS-TA, a triamcinolone acetonide",
          2.2048850933583716e-08
        ],
        [
          "2021 FDA approval of CLS-TA, a triamcinolone",
          1.208082865455579e-08
        ],
        [
          "2021 FDA",
          1.0138501133985958e-08
        ],
        [
          "2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension",
          9.610659973857238e-09
        ],
        [
          "the 202",
          1.0313671671365075e-10
        ],
        [
          "after the 202",
          3.1667140754167056e-11
        ],
        [
          "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 202",
          5.450430902821254e-12
        ],
        [
          "suprachoroidal space (SCS\u00ae) has become a clinical reality after the 202",
          2.8072124410450464e-12
        ],
        [
          "the 2021 FDA approval of CLS-TA",
          1.187448817825766e-12
        ],
        [
          "CLS-TA",
          9.839877935211994e-13
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6415b3b4690f196b51000009",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "yellow light",
          0.6318011706478669
        ],
        [
          "yellow",
          0.3681469109310437
        ],
        [
          "light",
          5.10845860507968e-05
        ],
        [
          "millisecond-timescale pulses of yellow light",
          3.154731660530044e-07
        ],
        [
          "millisecond-timescale pulses of yellow",
          1.8382440071289516e-07
        ],
        [
          "silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light",
          1.0509440825262821e-07
        ],
        [
          "enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow",
          6.192467156484103e-08
        ],
        [
          "silenced reliably, and reversibly, by millisecond-timescale pulses of yellow",
          6.123790767063163e-08
        ],
        [
          "Here we report",
          2.5541038349338337e-12
        ],
        [
          "Here we",
          1.063667607071133e-12
        ],
        [
          "light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis",
          1.0629734820035277e-12
        ],
        [
          "Here",
          1.0283874151344735e-12
        ],
        [
          "we report",
          9.671314544614265e-13
        ],
        [
          "report",
          7.992226899439714e-13
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6429fad757b1c7a31500000e",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "TATA box",
          1.464382287073932
        ],
        [
          "TATA\" box",
          0.9987612911958772
        ],
        [
          "TATAWAWR",
          0.5948340378312127
        ],
        [
          "TFIID",
          0.26781310812400316
        ],
        [
          "TATA-like element and their promoters are generally AT-rich;",
          0.18483317346762035
        ],
        [
          "TATAWAWR)",
          0.14907052646936048
        ],
        [
          "TFIID multiprotein complex",
          0.11751159371012292
        ],
        [
          "TATA-binding protein (TBP) is one of the major components of the human TFIID",
          0.07702292640755168
        ],
        [
          "TATA-binding protein (TBP) is one of the major components of the human TFIID multiprotein complex",
          0.033796280166309346
        ],
        [
          "TATA-like element",
          0.032369440200060856
        ],
        [
          "TATA",
          0.014824514034557788
        ],
        [
          "TATA box) found in many eukaryotic promoters",
          0.010887212181318691
        ],
        [
          "TBP binding to the TATA box",
          0.006537791057688836
        ],
        [
          "TATA-like element and their promoters",
          0.0033674358575821964
        ],
        [
          "TATA-like element and their promoters are generally AT-rich",
          0.0020182420050959974
        ],
        [
          "T",
          0.0019052268671247246
        ],
        [
          "TFIID multiprotein complex. It is important in directing the initiation of RNA transcription",
          0.0013190709954561516
        ],
        [
          "TATA-like element and their promoters are generally AT-rich; however",
          0.0012638944857329985
        ],
        [
          "TATA-like element and their promoters are generally AT-rich; however, only approximately 10%",
          0.0012121543416673162
        ],
        [
          "TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site",
          0.0005354701964253193
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64402e7757b1c7a315000044",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "9",
          0.9817438081275505
        ],
        [
          "Nineteen",
          0.9739069447722675
        ],
        [
          "Nineteen patients enrolled in the trial, and 18",
          0.02309471458921852
        ],
        [
          "9 subjects",
          0.017187415926407303
        ],
        [
          "Nine",
          0.0014159383252073856
        ],
        [
          "Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements",
          0.0006140820679022206
        ],
        [
          "9 subjects each cohort",
          0.0005320418575702198
        ],
        [
          "18",
          0.0004720095347524793
        ],
        [
          "Nineteen patients enrolled in the trial",
          0.0003073938293067262
        ],
        [
          "Nineteen patients",
          8.604303086210878e-05
        ],
        [
          "Nineteen patients enrolled",
          7.591835329351574e-05
        ],
        [
          "9 subjects each",
          4.799801689505751e-05
        ],
        [
          "Nineteen patients enrolled in the trial, and",
          1.2759523776399676e-05
        ],
        [
          "18 completed all safety and efficacy measurements",
          1.2550602868488428e-05
        ],
        [
          "enrolled in the trial, and 18",
          7.001664886319946e-07
        ],
        [
          "and 18",
          5.465425759856886e-07
        ],
        [
          "9 subjects each cohor",
          4.5984861130997633e-07
        ],
        [
          "patients enrolled in the trial, and 18",
          1.9900703685360455e-07
        ],
        [
          "the trial, and 18",
          1.3944971430303484e-07
        ],
        [
          "subjects",
          6.466101726022703e-08
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64425ce357b1c7a315000059",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "1 in 20000",
          0.919130985288516
        ],
        [
          "1:8000",
          0.910790106527367
        ],
        [
          "8000",
          0.07461661185405964
        ],
        [
          "20000",
          0.06621284273980244
        ],
        [
          "1:8000 incidence",
          0.0131826067966478
        ],
        [
          "about 1 in 20000",
          0.007214079862254688
        ],
        [
          "1 in 20000. Overall lifespan is not affected significantly",
          0.004869926862746304
        ],
        [
          "1",
          0.0013166835613708976
        ],
        [
          "8000 incidence",
          0.001079986977812655
        ],
        [
          "20000. Overall lifespan is not affected significantly",
          0.00035082236011893634
        ],
        [
          "approximate 1:8000",
          0.00016755960181352183
        ],
        [
          "1 in",
          0.00011692051676138653
        ],
        [
          "incidence of about 1 in 20000",
          0.00010272517337029025
        ],
        [
          "1 in 2000",
          0.00010002449117198663
        ],
        [
          "4 per 100000 and an incidence of about 1 in 20000",
          7.931907021467593e-05
        ],
        [
          "about 1 in 20000. Overall lifespan is not affected significantly",
          3.8223106253091107e-05
        ],
        [
          "around 4 per 100000 and an incidence of about 1 in 20000",
          3.173744647757532e-05
        ],
        [
          "an approximate 1:8000",
          2.114382726769824e-05
        ],
        [
          "an incidence of about 1 in 20000",
          1.3685068023746379e-05
        ],
        [
          "1:800",
          1.1900163812374104e-05
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63f581e933942b094c000007",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "spinal muscular atrophy",
          2.999585249647934
        ],
        [
          "SMA",
          0.9995334120015378
        ],
        [
          "motor neurons. Major advances and developments in SMA",
          0.00022215115678565097
        ],
        [
          "Major advances and developments in SMA",
          0.00015759945831999577
        ],
        [
          "Type 1 or 2 spinal muscular atrophy",
          0.00010816220260679191
        ],
        [
          "atrophy-is",
          0.00010333614409808343
        ],
        [
          "SMA therapeutics are shifting the natural history of the disease",
          7.201689203032608e-05
        ],
        [
          "spinal muscular atrophy (SMA)",
          7.17004010115696e-05
        ],
        [
          "atrophy",
          6.868273516645712e-05
        ],
        [
          "An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy",
          2.8368190735224944e-05
        ],
        [
          "spinal",
          2.5904682494358952e-05
        ],
        [
          "SMN1 produces SMN, a ubiquitously expressed protein",
          1.551226950007011e-06
        ],
        [
          "spinal muscular at",
          1.174055220926546e-06
        ],
        [
          "1 or 2 spinal muscular atrophy",
          6.433056135308947e-07
        ],
        [
          "spinal muscular atrophy-is presented here as a case study",
          5.069617076487292e-07
        ],
        [
          "or 2 spinal muscular atrophy",
          4.639016952498956e-07
        ],
        [
          "patients with Type 1 or 2 spinal muscular atrophy",
          4.418332798081694e-07
        ],
        [
          "\u22652 months of age with spinal muscular atrophy",
          3.237189021028371e-07
        ],
        [
          "SMN1 produces SMN",
          2.6440739801691144e-07
        ],
        [
          "risdiplam for patients with Type 1 or 2 spinal muscular atrophy",
          2.2193457261750895e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6431f7de57b1c7a31500001b",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "frataxin",
          6.995679592224605
        ],
        [
          "frataxin (FXN) gene",
          0.0010033163661876954
        ],
        [
          "f",
          0.000598896796040119
        ],
        [
          "frataxin in whole blood from healthy controls and homozygous FRDA",
          0.00027548457108659175
        ],
        [
          "frataxin (FXN)",
          7.735141478151836e-05
        ],
        [
          "Simultaneous Quantification of Mitochondrial Mature Frataxin",
          4.5111641519496456e-05
        ],
        [
          "Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood",
          3.937164143252016e-05
        ],
        [
          "frataxin proteoforms in whole blood from healthy controls and FRDA patients",
          2.7188889051813164e-05
        ],
        [
          "Mitochondrial Mature Frataxin",
          2.60802952686661e-05
        ],
        [
          "Frataxin and Extra-Mitochondrial Frataxin",
          2.0339848859520943e-05
        ],
        [
          "Quantification of Mitochondrial Mature Frataxin",
          1.3489629650053794e-05
        ],
        [
          "frataxin in whole blood from healthy controls",
          1.1841909785417938e-05
        ],
        [
          "Frataxin and Extra-Mitochondrial Frataxin Isoform E",
          1.0991010320251386e-05
        ],
        [
          "frataxin in whole blood from healthy controls and homozygous FRDA patients",
          9.369964596037066e-06
        ],
        [
          "frataxin in whole blood from healthy controls and homozygous",
          8.273394388163939e-06
        ],
        [
          "We now report a quantitative assay for frataxin",
          5.747258091620363e-06
        ],
        [
          "frataxin proteoforms in whole blood from healthy controls and FRDA",
          3.82687940557444e-06
        ],
        [
          "FXN",
          3.622911606850673e-06
        ],
        [
          "frataxin (FXN) gene, which leads to reduced expression of full-length frataxin",
          2.873941072864892e-06
        ],
        [
          "frataxin (FXN) gene, which leads to reduced expression of full-length frataxin (1-210)",
          2.454847908513641e-06
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "643f9eeb57b1c7a31500003c",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "19.7",
          0.8834507730512673
        ],
        [
          "1:5,000 live male births",
          0.845205832494688
        ],
        [
          "1:5,000",
          0.14975108470818005
        ],
        [
          "The cumulative incidence of disease was 19.7",
          0.07329975420415798
        ],
        [
          "19.7 per 100,000 male live births",
          0.027985410474634806
        ],
        [
          "7",
          0.0034826030157781634
        ],
        [
          "19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD",
          0.0030321857451666837
        ],
        [
          "5,000 live male births",
          0.002976905919625196
        ],
        [
          "19.7 per 100,000 male live births and 1 in 5076",
          0.0028478413406825462
        ],
        [
          "The cumulative incidence of disease was 19.7 per 100,000 male live births",
          0.002321944551600001
        ],
        [
          "19",
          0.0018923415317666599
        ],
        [
          "1",
          0.0012193522930520127
        ],
        [
          "5,000",
          0.0005274394394821892
        ],
        [
          "19.7 per 100,000",
          0.0002573753756152223
        ],
        [
          "cumulative incidence of disease was 19.7",
          0.00023911810900101828
        ],
        [
          "The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076",
          0.00023628489175860022
        ],
        [
          ".7",
          0.00021558614453530338
        ],
        [
          "overall incidence of 1:5,000 live male births",
          0.00016922605621638278
        ],
        [
          "The cumulative incidence of disease was 19",
          0.00015437539887826668
        ],
        [
          "1 in 5076 live born males were diagnosed with DMD",
          0.00015014093995538723
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6415c252690f196b51000011",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "bladder cancer",
          1.0014558392742312
        ],
        [
          "Cancer",
          0.5698496573590969
        ],
        [
          "Non-muscle Invasive Bladder Cancer",
          0.2873174819867001
        ],
        [
          "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer",
          0.08203551440243899
        ],
        [
          "Treatment of Non-muscle Invasive Bladder Cancer",
          0.04496074024391541
        ],
        [
          "bladder",
          0.007211899639680274
        ],
        [
          "the Treatment of Non-muscle Invasive Bladder Cancer",
          0.004004944375482357
        ],
        [
          "for the Treatment of Non-muscle Invasive Bladder Cancer",
          0.0013042581065547028
        ],
        [
          "muscle Invasive Bladder Cancer",
          0.0005483706143076166
        ],
        [
          "of Non-muscle Invasive Bladder Cancer",
          0.0005451769877991844
        ],
        [
          "Invasive Bladder Cancer",
          0.00040726885566353364
        ],
        [
          "-muscle Invasive Bladder Cancer",
          0.00023790708104607776
        ],
        [
          "Cancer: History and Current Status",
          6.259246378179648e-05
        ],
        [
          "Non-muscle Invasive Bladder Cancer: History and Current Status",
          3.15271948105918e-05
        ],
        [
          "Non-muscle Invasive Bladder",
          6.09817843091612e-06
        ],
        [
          "Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status",
          4.939729864530282e-06
        ],
        [
          "Bladder Cancer: History and Current Status",
          1.0082845879037859e-06
        ],
        [
          "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder",
          9.926473776223876e-07
        ],
        [
          "bladder cancer, especially for intermediate and high-risk groups",
          9.043614522186534e-07
        ],
        [
          "Treatment of Non-muscle Invasive Bladder",
          5.440346321246092e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63eeed0af36125a426000007",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Multiple Myeloma",
          4.999107516469644
        ],
        [
          "myeloma",
          0.0007146671727374653
        ],
        [
          "Multiple",
          0.00015594688382517658
        ],
        [
          "Teclistamab in Relapsed or Refractory Multiple Myeloma",
          6.62066296809761e-06
        ],
        [
          "Relapsed or Refractory Multiple Myeloma",
          5.3775622953903154e-06
        ],
        [
          "multiple myelo",
          2.661075152258468e-06
        ],
        [
          "multiple myeloma cells in preclinical studies",
          2.1939511632671746e-06
        ],
        [
          "patients with triple-class-exposed relapsed or refractory multiple myeloma",
          5.153619363649713e-07
        ],
        [
          "in Relapsed or Refractory Multiple Myeloma",
          4.892410944461603e-07
        ],
        [
          "Multiple My",
          4.430472368348266e-07
        ],
        [
          "Refractory Multiple Myeloma",
          3.735112772567295e-07
        ],
        [
          "teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma",
          3.595586310224704e-07
        ],
        [
          "or Refractory Multiple Myeloma",
          3.5537558404102357e-07
        ],
        [
          "patients with relapsed or refractory multiple myeloma",
          3.54808859191898e-07
        ],
        [
          "Teclistamab for Multiple Myeloma",
          2.0642706228478604e-07
        ],
        [
          "potent T-cell-mediated cytotoxicity of multiple myeloma",
          1.969437587055545e-07
        ],
        [
          "T-cell-mediated cytotoxicity of multiple myeloma",
          1.6822623158577382e-07
        ],
        [
          "triple-class-exposed relapsed or refractory multiple myeloma",
          1.4886318309092992e-07
        ],
        [
          "in patients with relapsed or refractory multiple myeloma",
          1.449739348149995e-07
        ],
        [
          "CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma",
          1.2410537155485662e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63f03ea0f36125a426000020",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Clostridioides difficile",
          1.9991984785996189
        ],
        [
          "C. difficile",
          0.9998978843955789
        ],
        [
          "rCDI",
          0.9348228294179531
        ],
        [
          "SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI",
          0.013906862471629916
        ],
        [
          "reducing rCDI",
          0.006975422187136728
        ],
        [
          "oral microbiome therapeutic, was superior to placebo in reducing rCDI",
          0.006349071562910379
        ],
        [
          "investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI",
          0.005368339568488483
        ],
        [
          "placebo in reducing rCDI",
          0.004176377907038482
        ],
        [
          "an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI",
          0.0031889712328002588
        ],
        [
          "microbiome therapeutic, was superior to placebo in reducing rCDI",
          0.002940001317621113
        ],
        [
          "in reducing rCDI",
          0.002803562198968872
        ],
        [
          "superior to placebo in reducing rCDI",
          0.002361473319918313
        ],
        [
          "was superior to placebo in reducing rCDI",
          0.0015825427569649943
        ],
        [
          "Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus",
          0.0005874313837551634
        ],
        [
          "difficile",
          0.00015968463471676
        ],
        [
          "C",
          7.964925351333514e-05
        ],
        [
          "rCD",
          3.4825374685206106e-05
        ],
        [
          "r",
          2.9804628937254773e-05
        ],
        [
          "SARS",
          2.4718644059840206e-05
        ],
        [
          "Clostridioides difficile Infection",
          2.0272811248641748e-05
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64179113690f196b5100002e",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Xp21",
          1.8929858799565016
        ],
        [
          "Xp21 chromosome locus",
          0.916880819509617
        ],
        [
          "Xp21)",
          0.03222467941486838
        ],
        [
          "X",
          0.007101124203427595
        ],
        [
          "X chromosome (Xp21)",
          0.007003972389600984
        ],
        [
          "Xp21 chromosome",
          0.0029703847997806006
        ],
        [
          "X chromosome",
          0.0019172394284227908
        ],
        [
          "the Xp21 chromosome locus",
          0.00011772959679448897
        ],
        [
          "Xp",
          6.148748767668779e-05
        ],
        [
          "(Xp21)",
          4.95663022719157e-05
        ],
        [
          "Xp21 chromosome lo",
          4.825261888930391e-05
        ],
        [
          "the X chromosome (Xp21)",
          1.2165575170999575e-05
        ],
        [
          "mapping on the Xp21 chromosome locus",
          1.1694670090687687e-05
        ],
        [
          "the Xp21",
          9.877757036706838e-06
        ],
        [
          "the X chromosome",
          4.519482865512943e-06
        ],
        [
          "on the Xp21 chromosome locus",
          3.1720232537205902e-06
        ],
        [
          "at Xp21",
          1.972438526339215e-06
        ],
        [
          "locus",
          1.430592500101122e-06
        ],
        [
          "mapping on the Xp21",
          1.000361549921797e-06
        ],
        [
          "dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus",
          8.601284109344231e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6415c9e9690f196b51000018",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "mTNBC",
          0.9999554489512755
        ],
        [
          "m",
          1.542804794179315e-05
        ],
        [
          "PD-L1-positive mTNBC",
          2.459570700506613e-06
        ],
        [
          "positive mTNBC",
          1.1906865911515038e-06
        ],
        [
          "mTNBC, as the FDA recently approved atezolizumab (Tecentriq) and pembrolizumab",
          9.335135452389982e-07
        ],
        [
          "chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC",
          8.105677300375954e-07
        ],
        [
          "mTNBC, as the FDA recently approved atezolizumab",
          7.75195198252012e-07
        ],
        [
          "-positive mTNBC",
          5.739843181625684e-07
        ],
        [
          "for PD-L1-positive mTNBC",
          4.602385455127079e-07
        ],
        [
          "mTNBC, as the FDA recently approved atezolizumab (Tecentriq)",
          4.373335501581429e-07
        ],
        [
          "immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC",
          3.6620701552592235e-07
        ],
        [
          "mT",
          2.6616782209615983e-07
        ]
      ]
    }
  ]
}